- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | H.C. Wainwright bestätigt Kaufempfehlung für Zenas Biopharma nach Studienerfolg | 1 | Investing.com Deutsch | ||
| Mi | H.C. Wainwright reiterates Zenas Biopharma stock rating at buy | 1 | Investing.com | ||
| Mi | Zenas BioPharma reports positive phase 3 trial results for obexelimab | 2 | Investing.com | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | 2 | GlobeNewswire (USA) | ||
| 28.05. | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | 307 | GlobeNewswire (Europe) | - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq:... ► Artikel lesen | |
| 19.05. | Zenas BioPharma präsentiert Studiendaten zu Obexelimab auf dem EULAR-Kongress | 1 | Investing.com Deutsch | ||
| 19.05. | Zenas BioPharma to present obexelimab trial data at EULAR congress | 3 | Investing.com | ||
| 19.05. | Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | 197 | GlobeNewswire (Europe) | - Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT - WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 18.05. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 13.05. | Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor | 183 | GlobeNewswire (Europe) | - Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - -... ► Artikel lesen | |
| 13.05. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Zenas BioPharma GAAP EPS of -$1.46 beats by $0.22 | 2 | Seeking Alpha | ||
| 13.05. | Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update | 431 | GlobeNewswire (Europe) | - Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results - - Obexelimab... ► Artikel lesen | |
| 30.04. | Zenas BioPharma rises as CEO continues insider purchases | 1 | Seeking Alpha | ||
| 17.04. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 31.03. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Zenas BioPharma Prices $300M Capital Raise in Dual Offering | 4 | Seeking Alpha | ||
| 27.03. | Zenas BioPharma prices $200M convertible notes, $100M stock sale | 3 | Investing.com | ||
| 27.03. | Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million | 1 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 306,30 | +0,97 % | Während Merck, Amgen, Novo Nordisk und Fresenius Milliarden bewegen, wächst die Fantasie im Zelltherapie-Sektor | ||
| REGENERON PHARMACEUTICALS | 551,40 | +0,04 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,500 | +0,49 % | BIOMARIN PHARMACEUTICAL INC - 8-K, Current Report | ||
| ARROWHEAD PHARMACEUTICALS | 62,84 | -0,91 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| INSMED | 82,00 | +0,26 % | RBC Capital senkt Kursziel für Insmed auf 195 $ | ||
| SWEDISH ORPHAN BIOVITRUM | 41,100 | +1,18 % | Swedish Orphan Biotrauma AB: Sobi to present new data on pegcetacoplan at ERA 2026 | STOCKHOLM, June 1, 2026 /PRNewswire/ -- Sobi today announced that new data from the pegcetacoplan clinical development programme and related research in C3 glomerulopathy (C3G) and primary... ► Artikel lesen | |
| SCHOLAR ROCK | 39,060 | +1,67 % | Scholar Rock Holding Corp - 8-K, Current Report | ||
| CRINETICS PHARMACEUTICALS | 28,980 | +1,51 % | Crinetics Pharmaceuticals, Inc.: Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations | Oral presentation features open label extension PALSONIFY (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals
Two oral presentations... ► Artikel lesen | |
| PROQR THERAPEUTICS | 1,302 | -0,31 % | ProQR Therapeutics N.V. - 6-K, Report of foreign issuer | ||
| ENSYSCE BIOSCIENCES | 0,250 | -1,61 % | Ensysce Biosciences Reports First Quarter 2026 Financial Results | ~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR Patent Estate Expanded ~~ Company Launches Formal Review of Strategic... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 48,380 | -0,08 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| TEVOGEN BIO | 10,480 | +0,10 % | Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue | WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen |
ZENAS BIOPHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,040 (-0,23 %) liegt der Kurs bei 17,430 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.